Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

3.1K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.1K
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

2.0K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
2.0K
Cholecystitis01:20

Cholecystitis

22
Cholecystitis is inflammation of the gallbladder, most commonly caused by obstruction of the cystic duct. This blockage prevents bile from draining, leading to gallbladder distension, inflammation, and potentially serious complications. This condition may present acutely or chronically and can happen with or without gallstones.EtiologyAbout 95% of cholecystitis cases are calculous, caused by gallstones blocking the cystic duct, leading to bile accumulation and inflammation of the gallbladder...
22
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

698
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
698
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

744
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
744
Pharmaceutical Poisoning: Treatment Strategies01:26

Pharmaceutical Poisoning: Treatment Strategies

271
Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
271

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Introducing EULAR Rheumatology Open (ERO): A New Platform for Advancing Rheumatology Research.

EULAR rheumatology open·2026
Same author

Prognostic Value of Bronchoalveolar Lavage in Systemic Autoimmune Rheumatic Diseases-Associated Interstitial Lung Disease.

Journal of clinical medicine·2026
Same author

Detectable safety gestalt of rheumatoid arthritis treatments from pivotal clinical drug trials.

Rheumatology (Oxford, England)·2026
Same author

Time-resolved immune dynamics in rheumatoid arthritis under methotrexate therapy.

Annals of the rheumatic diseases·2026
Same author

Evaluating machine learning tools to assist title and abstract screening in systematic literature reviews: a report based on the EULAR RA Management Recommendations Task Force.

Annals of the rheumatic diseases·2026
Same author

Chasing the target: reports from the Advances in Targeted Therapies meeting, 2025.

Annals of the rheumatic diseases·2026

Related Experiment Video

Updated: Apr 25, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

2.5K

Colchicine for acute gout.

Irene van Echteld1, Mihir D Wechalekar, Naomi Schlesinger

  • 1Department of Rheumatology, St Elisabeth Hospital, Hilvarenbeekseweg 60, Tilburg, Netherlands, 5022GC.

The Cochrane Database of Systematic Reviews
|August 16, 2014
PubMed
Summary

Low-dose colchicine shows promise for acute gout treatment, offering pain relief with fewer adverse events than high-dose regimens. Further research is needed to compare colchicine with other common gout medications.

More Related Videos

An Automated Method to Perform The In Vitro Micronucleus Assay using Multispectral Imaging Flow Cytometry
12:56

An Automated Method to Perform The In Vitro Micronucleus Assay using Multispectral Imaging Flow Cytometry

Published on: May 13, 2019

25.0K
Preparation Of Gushukang GSK Granules for In Vivo and In Vitro Experiments
06:16

Preparation Of Gushukang GSK Granules for In Vivo and In Vitro Experiments

Published on: May 9, 2019

6.8K

Related Experiment Videos

Last Updated: Apr 25, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

2.5K
An Automated Method to Perform The In Vitro Micronucleus Assay using Multispectral Imaging Flow Cytometry
12:56

An Automated Method to Perform The In Vitro Micronucleus Assay using Multispectral Imaging Flow Cytometry

Published on: May 13, 2019

25.0K
Preparation Of Gushukang GSK Granules for In Vivo and In Vitro Experiments
06:16

Preparation Of Gushukang GSK Granules for In Vivo and In Vitro Experiments

Published on: May 9, 2019

6.8K

Area of Science:

  • Rheumatology
  • Pharmacology
  • Clinical Trials

Background:

  • Gout is a prevalent rheumatic disease globally.
  • Colchicine is a first-line therapy for acute gout, but evidence on its efficacy and safety is limited.
  • This review updates previous findings on colchicine's benefits and harms.

Purpose of the Study:

  • To evaluate the benefits and harms of colchicine for acute gout treatment.
  • To synthesize evidence from randomized controlled trials (RCTs) and controlled clinical trials (CCTs).

Main Methods:

  • Searched multiple databases (CENTRAL, MEDLINE, EMBASE) and trial registers up to April 2014.
  • Included RCTs and CCTs comparing colchicine with placebo or active treatments for acute gout.
  • Assessed pain reduction (≥50% decrease) and adverse events (participant withdrawal).
  • Evaluated evidence quality using the GRADE approach.

Main Results:

  • Low-dose colchicine demonstrated efficacy in pain reduction compared to placebo (NNTB=5).
  • High-dose colchicine also reduced pain (NNTB=4) but was associated with significantly more adverse events (NNTH=2).
  • Low-dose colchicine showed no significant increase in adverse events compared to placebo.
  • No trials compared colchicine with NSAIDs or glucocorticoids.

Conclusions:

  • Low-dose colchicine appears to be an effective treatment for acute gout with a favorable safety profile.
  • High-dose colchicine is effective but carries a higher risk of adverse events.
  • Low-dose colchicine may be the preferred treatment option due to its balance of efficacy and safety.
  • Further research is needed on colchicine in comorbid populations and against other common treatments.